NIH Continues Support of Kent State Alzheimer’s Researcher with New 2-Year Grant
Once it begins, Alzheimer’s Disease progresses systematically and aggressively, attacking victims on multiple fronts. But scientists studying the disease operate the same way — like Kent State University’s own Dr. Gemma Casadesus Smith.
Since 2016, Casadesus Smith, an associate professor of biological science in the College of Arts and Sciences, has received more than $2.7 million in funding from the National Institutes of Health to study the causes of Alzheimer’s and identify models for better pharmacological treatments.
A new two-year, $224,500 project, titled “Characterization of transcriptome changes in diet-induced progression to METS/T2D to identify earliest and sex-specific neurodegenerative foci for AD development,” allows her to pursue answers to some important questions that have arisen during those studies.
“We know that diabetes and obesity are related to Alzheimer’s Disease — diabetes is the number one risk factor other than age — and we know that if we look at an Alzheimer’s brain, we’ll see changes in insulin receptors, but we don’t understand how that transition occurs,” Casadesus Smith said.
Using data and material from her ongoing study of a drug designed to prevent formation of amylin plaques — one suspected contributing factor to Alzheimer’s development — Casadesus Smith will use gene sequencing technology to better understand the differences in Alzheimer’s progression in males and females, and identify genetic changes from the earliest point of metabolic dysfunction to the onset of Alzheimer’s.
Her ongoing studies with rodent models have shown a clear link between a high-fat diet and earlier appearance of Alzheimer’s markers in the brain. Working with Dr. Helen Piontkivska — professor of biological sciences, specializing in bioinformatics and medical genomics, especially large scale analysis of genomic sequences — Casadesus Smith will run brain tissue samples through RNA sequencing to show changes in each individual gene at each stage of transition.
“We will be able to identify the transcriptional targets within the brain that change early on in states of metabolic stress, and by looking at those, it may give us an idea of early foci that link diseases of metabolism such as diabetes to Alzheimer’s disease development,” she said.
The study also seeks to identify the differences in Alzheimer’s pathology between males and females. While males are at higher risk for metabolic dysfunction like obesity and diabetes than females, when females develop those conditions, they are at higher risk of developing cognitive dysfunction and Alzheimer’s than males.
Casadesus Smith said she’s hopeful the short study will yield enough data to advance to a larger funded project.
“We’re going to be able to piece together the transcriptional changes with what we see in the brain, in terms of pathology and metabolism,” she said. “Hopefully we will be able to identify specific proteins or receptors or changes that then can be looked at in a larger study and pursued in a hypothesis-based manner.”